On September 4, 2024, iRhythm Technologies, a leader in digital healthcare focused on cardiac monitoring solutions, announced an exclusive license agreement with BioIntelliSense. This partnership will leverage BioIntelliSense’s advanced multiparameter sensing technologies to enhance iRhythm's ambulatory cardiac monitoring (ACM) platform. BioIntelliSense offers medical-grade wearables and data services, including the FDA-cleared BioButton and innovative pulse oximetry capabilities, which will be integrated into iRhythm’s offerings to broaden clinical insights and improve patient care.
The agreement grants iRhythm the rights to develop and commercialize BioIntelliSense’s pulse oximetry, accelerometry, and non-invasive blood pressure technologies within its ACM products. This collaboration aims to address gaps in current healthcare monitoring by providing clinicians with actionable data for timely interventions. BioIntelliSense will receive upfront payments and royalties based on future sales and regulatory milestones. This strategic move aligns with iRhythm’s goal to advance continuous monitoring and digital health solutions, reinforcing its position as a market leader in cardiac care and beyond.
